Consultants Forum Advertise
Subscribe
Close

  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Subscribe Now
Renew

Area Development - Site Selection, Facility Planning and Workforce Development

Glaukos Plans Huntsville, Alabama, Manufacturing-Research Operations

10/18/2025
Glaukos Corp., a company specializing in ophthalmic pharmaceuticals and medical technologies, plans to establish operations in Huntsville, Alabama. The over $80 million project is expected to create more than 150 jobs.

The investment will include the construction of a 200,000-square-foot research, development and manufacturing facility, located at Cummings Research Park, dedicated to developing novel therapies for glaucoma, corneal disorders and retinal diseases.

“After evaluating over 100 potential sites worldwide, we ultimately chose Huntsville for its strong talent base and vibrant business climate,” said Thomas Burns, Glaukos Chairman and CEO. “We appreciate our new partnership with the City of Huntsville and look forward to the ophthalmic innovations that will emerge from this strategic expansion as we continue advancing our mission to transform vision therapies for patients living with chronic eye diseases.”

Glaukos develops and commercializes novel therapies for chronic eye diseases like glaucoma, corneal disorders, and retinal diseases. The company is known for pioneering Micro-Invasive Glaucoma Surgery (MIGS) with its iStent products and is dedicated to transforming vision through innovation in surgical and pharmaceutical solutions.

“Glaukos is exactly the kind of visionary company we want growing in Alabama,” noted Ellen McNair, Secretary of the Alabama Department of Commerce. “Their investment in Huntsville is a powerful endorsement of our state’s skilled workforce, world-class research assets and pro-business environment,” Secretary McNair said. “This project also reflects the strength of our comprehensive economic development strategic plan ‘Catalyst’ — one focused on innovation, execution and long-term impact.”

“Glaukos’ investment is a clear signal that our state is not only competing, but winning, in attracting cutting-edge biotech and health innovation,” added Alex Cate, a Senior Project Manager at the Alabama Department of Commerce who specializes in the biosciences sector.

Exclusive Research